A comprehensive comparative review of adenosine diphosphate receptor antagonists

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 2, 2012, Pages 175-191

  Oh, Erin Y ^a   Abraham, Teena ^a   Saad, Nasser ^a   Rapp, Jonathan H ^a   Vastey, Fabienne L ^a   Balmir, Eric ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

ADP receptor antagonist; Clopidogrel; P2Y12 antagonist; Prasugrel; Ticagrelor

Indexed keywords

ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST; ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 2C19; LANSOPRAZOLE; MEVINOLIN; OMEPRAZOLE; PLACEBO; PRASUGREL; RECEPTOR BLOCKING AGENT; SIMVASTATIN; TICAGRELOR; UNCLASSIFIED DRUG;

BACKACHE; BLEEDING; BRADYCARDIA; COLON CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; GENETIC POLYMORPHISM; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LOADING DRUG DOSE; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADENOSINE; DRUG INTERACTIONS; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84855904383     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.647683     Document Type: Review

References (87)

1. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2011;123:2022-60
2. Kushner FG, Hand M, Smith SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (Updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (Updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2009;54:2205-41
3. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8 (Pubitemid 46328299)
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-157
5. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990;82:17-26 (Pubitemid 20216311)
6. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine: Prevention, recognition and management. Drug Saf 1998;19:89-98 (Pubitemid 28389035)
7. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502 (Pubitemid 32758501)
8. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20 (Pubitemid 35340537)
9. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
10. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
11. Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA 'Boxed Warning': a report of the American College of Cardiology Foundation task force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56:321-41
12. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60
13. Duggan ST, Keating GM. Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Drugs 2009;69:1707-26
14. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008;36:1227-32 (Pubitemid 351929304)
15. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-7
16. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
17. Ticagrelor [package insert]. AstraZeneca; Wilmington, DE: 2011
18. Clopidogrel [package insert]. Sanofi-aventis; Bridgewater, NJ: 2011
19. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4 (Pubitemid 40740853)
20. Prasugrel [package insert]. Eli Lilly; Indianapolis, IN: 2010
21. Reinhart KM, White CM, Baker WL. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy 2009;29:1441-51
22. Niitsu Y, Sugidachi A, Ogawa T, et al. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur J Pharmacol 2008;579:276-82
23. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6 (Pubitemid 350017792)
24. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85
25. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol 2011;51:978-87
26. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
27. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33 (Pubitemid 32772726)
28. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008;118:1626-36
29. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet 2009;373:723-31
30. Dobesh PP. Clopidogrel versus prasugrel: times are changing, but not for everyone. Pharmacotherapy 2009;29:1393-6
31. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32 (Pubitemid 350291199)
32. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2009;157:599-605
33. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
34. De Servi S, Savonitto S. How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial? Int J Cardiol 2011;149:265-7
35. Schomig A. Ticagrelor - is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361:1108-11
36. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome intended for non-invasive management: substudy from prospective randomized platelet inhibition and patient outcomes (PLATO) trial. BMJ 2011;342:d3527
37. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2011;57:672-84
38. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention. Circulation 2010;122:2131-41
39. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the platelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 2010;31:3006-16
40. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function. Circulation 2010;122:1056-67
41. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011;124:544-54
42. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Am Coll Cardiol 2008;51:2028-33
43. Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insight from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Circulation 2011;123:2681-9
44. Wiviott SD, Desai N, Murphy SA, et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agency. Am J Cardiol 2011;108:905-11
45. Ticagrelor NDA 22-433. Briefing document for cardiovascular and renal drugs advisory committee meeting. Advisory Committee Briefing Document. Available from: http://www.fda.gov/downloads/AdvisoryCommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/UCM220197.pdf [Last accessed 2 December 2011]
46. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
47. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
48. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYodardial Damage during Angioplasty) study. Circulation 2005;111:2099-106 (Pubitemid 40577905)
49. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-31 (Pubitemid 47069129)
50. Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Int 2008;1:612-19
51. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Int 2008;1:631-8
52. Mehta SR, Bassand J, Chrolavicius S, et al. Dose comparison of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42
53. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not clopidogrel. J Thromb Haemost 2007;5:2429-36 (Pubitemid 350154353)
54. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009;30:1744-52
55. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-19
56. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010;3:556-66
57. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8
58. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effects of switching therapies: the RESPOND study. Circulation 2010;121:1188-99
59. Gilard M, Arnaud B, Cornily J, et al. Influence on omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
60. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
61. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5
62. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18
63. Medco study: PPIs reduce clopidogrel efficacy post-stenting. Cardiobrief. Available from: http://cardiobrief.org/2009/05/06/scai-clopidogrelppi-wed- 1130am [Last accessed 9 August 2011]
64. A common class of GI medications reduce protection against heart attack in patients taking widely prescribed cardiovascular drug. Medco MediaRoom. Available from: http://medco.mediaroom. com/index.php?s=43&item=352 [Last accessed 29 July 2010]
65. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009;43:1266-74
66. Fernando H, Bassler N, Habersberger J, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011;9:1582-9
67. Moceri P, Doyen D, Cerboni P, et al. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res 2011;128:458-62
68. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
69. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on expert consensus documents. Circulation 2010;122:2619-33
70. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84 (Pubitemid 351389118)
71. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
72. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug- drug interaction. Circulation 2003;107:32-7 (Pubitemid 36070929)
73. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel. Arch Intern Med 2004;164:2051-7 (Pubitemid 39390564)
74. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4 (Pubitemid 37048218)
75. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5 (Pubitemid 47058889)
76. Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008;28:1483-94
77. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945-53
78. Storey RF, Becker RC, Cannon CP, et al. Ticagrelor does not affect pulmonary function tests compared to clopidogrel in acute coronary syndromes: results of the PLATO pulmonary substudy. J Am Coll Cardiol 2010;55:A108.E1007
79. Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56:185-93
80. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2007;50:1844-51 (Pubitemid 350007959)
81. Scirica BM, Cannon CP, Emanuelsson H, et al. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:1908-16
82. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
83. Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011;105(Suppl 1):S75-81
84. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29
85. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41
86. A clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention (PCI) (CHAMPION PHOENIX). ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT01156571?term=champion +phoenix&rank=1 [Last accessed 30 November 2011]
87. Leonardi S, Rao SV, Harrington RA, et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12- receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-PCI). Am Heart J 2010;160:65-72